<DOC>
	<DOCNO>NCT00863655</DOCNO>
	<brief_summary>There treatment specifically approve recurrence progression non steroidal aromatase inhibitor ( NSAI ) . In light need new treatment option postmenopausal woman failure prior NSAI therapy , purpose Phase III study compare efficacy safety treatment exemestane + everolimus exemestane + placebo postmenopausal woman estrogen receptor positive locally advanced metastatic breast cancer refractory NSAI .</brief_summary>
	<brief_title>Everolimus Combination With Exemestane Treatment Postmenopausal Women With Estrogen Receptor Positive Locally Advanced Metastatic Breast Cancer Who Are Refractory Letrozole Anastrozole</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Adult woman ( â‰¥ 18 year age ) metastatic locally advanced breast cancer amenable curative treatment surgery radiotherapy . Histological cytological confirmation estrogenreceptor positive ( ER+ ) breast cancer Postmenopausal woman . Disease refractory non steroidal aromatase inhibitor ( NSAI ) , Radiological clinical evidence recurrence progression last systemic therapy prior randomization . Patients must least one lesion accurately measure bone lesion absence measurable disease define . HER2overexpressing patient Patients nonmeasurable lesion bone metastasis ( e.g . pleural effusion , ascites etc. ) . Patients receive one chemotherapy line Advanced Breast Cancer . Previous treatment exemestane mTOR inhibitor . Known hypersensitivity mTOR inhibitor , e.g . sirolimus ( rapamycin ) . Radiotherapy within four week prior randomization Currently receive hormone replacement therapy , Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Estrogen Receptor positive</keyword>
	<keyword>ER+</keyword>
	<keyword>exemestane</keyword>
	<keyword>mTOR</keyword>
	<keyword>everolimus</keyword>
	<keyword>refractory</keyword>
	<keyword>NSAI</keyword>
</DOC>